PTK2 and non-small cell lung carcinoma: Collectively, our data indicates that inhibition of FAK with PF-562271 in combination with erlotinib can effectively reduce the cell viability of NSCLC, specifically in smokers who develops resistance to EGFR-TKI therapy.